论文部分内容阅读
目的 :了解小 /中剂量氨酰心安对Ⅱ型糖尿病 (NIDDM)合并冠心病患者预后的影响。方法 :应用随机、实验对照法观察氨酰心安 (2 5mg～ 50mg/d)长期应用NIDDM合并冠心病患者死亡率的影响。结果 :通过 9～ 34个月的观察 ,氨酰心安组死亡率 1 0 4% (其中心源性 5 2 % ,其它 5 2 % ) ,对照组为 1 9 1 % (其中心源性 1 3 5 % ,其它 5 6 % )。结论 :使用 β受体阻滞剂氨酰心安有利于糖尿病合并冠心病患者生存 ,提高患者的生活质量
Objective: To understand the effect of small / medium dose Atenolol on the prognosis of type 2 diabetes mellitus (NIDDM) patients with coronary heart disease. Methods: A randomized, controlled trial was used to observe the effect of Atenolol (25mg ~ 50mg / d) on mortality in patients with NIDDM complicated with coronary heart disease. Results: After 9 to 34 months of observation, the mortality of atenolol group was 104% (52% of the cardinal centers and 52% of the other groups), while the control group was 119% (of which the cardiogenic 13 5%, other 56%). Conclusion: The use of beta-blocker Atenolol is beneficial to the survival of diabetic patients with coronary heart disease and improve the quality of life of patients